MBMary E. Brandt

Mary E. Brandt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mary E. Brandt has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • David W. Warnock

    2 shared publications
  • Lynne Sigler

    University of Alberta Microfungus Collection and Herbarium, Devonian Botanic Garden, Edmonton, Alberta, Canada

    2 shared publications
  • Naureen Iqbal

    Mycotic Diseases Branch, Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia,1 University Hygienic Laboratory, Iowa City, Iowa,2 Biodiversity Theme (Mycology and Botany), Environmental Health Team, Agriculture and Agri-Food Canada, Eastern Cereal and Oilseed Research Centre, Ottawa, Ontario,3 Microfungus Collection and Herbarium, Devonian Botanic Garden, University of Alberta, Edmonton, Alberta, Canada4

    2 shared publications
  • S. Arunmozhi Balajee

    Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333,1 Emory University Hospital, Atlanta, Georgia 303292

    2 shared publications
  • Shawn R. Lockhart

    Mycotic Diseases Branch, Centers for Disease Control and Prevention

    2 shared publications
  • Andre N. Sofair

    Yale University School of Medicine, New Haven, Connecticut, USA

    1 shared publication

Latest Publications

  • Open Access

    Real-time PCR assays for genotyping of Cryptococcus gattii in North America

    by Erin J Kelley, Elizabeth M Driebe, Kizee Etienne, Mary E Brandt, James M Schupp, John D Gillece, Jesse S Trujillo, Shawn R Lockhart, Eszter Deak, Paul S Keim, et al.

    Cryptococcus gattii has been the cause of an ongoing outbreak starting in 1999 on Vancouver Island, British Columbia and spreading to mainland Canada and the US Pacific Northwest. In the course of the outbreak, C. gattii has been identified outside of its previously documented climate, habitat, and host disease. Genotyping of C. gattii is essential to understand the ecological and geographical expansion of this emerging pathogen. We developed and validated a mismatch amplification mutation assay (MAMA) real-time PCR panel for genotyping C. gattii molecular types VGI-VGIV and VGII subtypes a,b,c. Subtype assays were designed based on whole-genome sequence of 20 C. gattii strains. Publically available multilocus sequence typing (MLST) data from a study of 202 strains was used for the molecular type (VGI-VGIV) assay design. All assays were validated across DNA from 112 strains of diverse international origin and sample types, including animal, environmental and human. Validation revealed each assay on the panel is 100% sensitive, specific and concordant with MLST. The assay panel can detect down to 0.5 picograms of template DNA. The (MAMA) real-time PCR panel for C. gattii accurately typed a collection of 112 diverse strains and demonstrated high sensitivity. This is a time and cost efficient method of genotyping C. gattii best suited for application in large-scale epidemiological studies.


  • Filamentous Basidiomycetes in the Clinical Laboratory

    by Mary E. Brandt

    Filamentous basidiomycetes are difficult to identify in the clinical laboratory, mostly due to lack of sporulation, and their role as agents of fungal infection can be difficult to assess. More cases of infection with these agents are being reported as more laboratories gain proficiency with the recognition of their subtle morphologic features and the use of DNA-based methods for identification. Most infections occur in the respiratory tract and sinuses, although brain infection has been reported. Susceptibility testing suggests that these agents will respond well to azole drugs other than fluconazole.


  • Recent Taxonomic Developments with Candida and Other Opportunistic Yeasts

    by Mary E. Brandt, Shawn R. Lockhart

    Increases in susceptible patient populations and advances in identification methods have resulted in the continued recognition of novel yeasts as agents of human infection. Most of these agents are members of the well-recognized genera Candida, Cryptococcus, Trichosporon, and Rhodotorula. Some of these agents are “cryptic species,” members of species complexes, and may not be detectable using classical carbohydrate assimilation-based methods of yeast identification. Such species require DNA- or MALDI-based methods for correct identification, although sporadic isolates may not routinely require delineation to the individual species level. The coming end of the fungal taxonomy rules requiring separate names for sexual and asexual forms of the same fungus will hopefully allow greater clarity, as names for medically important yeast can now be based on the needs of the medical mycology community and the common goal of better communication between laboratory and clinician.


  • Laboratory Aspects of Medical Mycology

    by Mary E. Brandt, Shawn R. Lockhart, David W. Warnock


  • Atypical Aspergillus flavus Isolates Associated with Chronic Azole Therapy

    by Mary E. Brandt, Lalitha Gade, Cindy B. McCloskey, S. Arunmozhi Balajee

    A case of chronic sinus disease due to morphologically atypical Aspergillus flavus is described. Multiple fungal isolates sporulated poorly or not at all, displaying unusual color and microscopic morphology, including the absence of typical vesicles and phialides, which caused the isolates to resemble several other fungal genera superficially. The patient received multiple antifungal therapies over at least 10 years with various azole drugs, including voriconazole, itraconazole, and posaconazole. We speculate that this lengthy exposure to azole antifungal drugs may have caused or promoted the atypical morphology seen in these isolates.


  • Open Access

    DNA and the classical way: Identification of medically important molds in the 21st century

    by S. Arunmozhi Balajee, Lynne Sigler, Mary E. Brandt

    The advent of the 21st century has seen significant advances in the methods and practices used for identification of medically important molds in the clinical microbiology laboratory. Historically, molds have been identified by using observations of colonial and microscopic morphology, along with tables, keys and textbook descriptions. This approach still has value for the identification of many fungal organisms, but requires expertise and can be problematic in determining a species identification that is timely and useful in the management of high-risk patients. For the increasing number of isolates that are uncommon, atypical, or unusual, DNA-based identification methods are being increasingly employed in many clinical laboratories. These methods include the commercially available GenProbe assay, methods based on the polymerase chain reaction such as single-step PCR, RAPD-PCR, rep-PCR, nested PCR, PCR-RFLP, PCR-EIA, and more recent microarray-based, Luminex technology-based, and real-time PCR-based methods. Great variation in assay complexity, targets, and detection methods can be found, and many of these methods have not been widely used or rigorously validated. The increasing availability of DNA sequencing chemistry has made comparative DNA sequence analysis an attractive alternative tool for fungal identification. DNA sequencing methodology can be purchased commercially or developed in-house; such methods display varying degrees of usefulness depending on the breadth and reliability of the databases used for comparison. The future success of sequencing-based approaches will depend on the choice of DNA target, the reliability of the result, and the availability of a validated sequence database for query and comparison. Future studies will be required to determine sequence homology breakpoints and to assess the accuracy of molecular-based species identification in various groups of medically important filamentous fungi. At this time, a polyphasic approach to identification that combines morphologic and molecular methods will ensure the greatest success in the management of patients with fungal infections.


  • Open Access

    False-Positive Histoplasma capsulatum Gen-Probe Chemiluminescent Test Result Caused by a Chrysosporium Species

    by Mary E. Brandt, Dennis Gaunt, Naureen Iqbal, Shirley McClinton, Sarah Hambleton, Lynne Sigler

    We describe a case in which the Histoplasma capsulatum AccuProbe test displayed cross-reactivity with a respiratory isolate thought to be Histoplasma but not morphologically consistent with H. capsulatum . The isolate was later identified as the Chrysosporium anamorph of Nannizziopsis vriesii by sequence analysis and phenotypic data.


  • Fungemia Caused by Zygoascus hellenicus in an Allogeneic Stem Cell Transplant Recipient

    by Mary E. Brandt, Carol A. Kauffman, Peter G. Pappas, Naureen Iqbal, Beth A. Arthington-Skaggs, Wendy Lee-Yang, Maudy T. Smith

    Zygoascus hellenicus ( Candida hellenica ) was isolated from a blood culture from a patient who had received an allogeneic stem cell transplant. The isolate displayed an antifungal susceptibility pattern of decreased susceptibility to fluconazole and itraconazole, high susceptibility to voriconazole, and low susceptibility to caspofungin. The organism was misidentified by a commercial yeast identification system. This is the first reported case of human infection with this rare ascomycetous yeast.